Omniscan (Gadodiamide)

Omniscan (gadodiamide) is used as a gadolinium‑based contrast agent for magnetic resonance imaging procedures.

• Magnetic resonance imaging (MRI): Provides enhanced visualization of anatomical structures and pathology.
• Magnetic resonance angiography (MRA): Improves delineation of vascular anatomy and blood flow.
• Contrast‑enhanced central nervous system studies: Facilitates detection of lesions, tumors, and vascular abnormalities.

• Gadodiamide forms a stable chelate with gadolinium ions, which shortens the T1 relaxation time of nearby water protons. This results in increased signal intensity on T1‑weighted MRI scans, allowing clearer differentiation of tissues and vascular structures during imaging.

Adverse reactions may occur following administration of gadodiamide.

Common Side Effects

• Nausea: mild to moderate discomfort after injection.
• Headache: transient headache reported by some patients.
• Injection site pain: brief discomfort at the site of intravenous administration.
• Warmth sensation: feeling of warmth or flushing during injection.
• Metallic taste: temporary metallic sensation in the mouth.
• Dizziness: occasional light‑headedness post‑dose.

Serious or Rare Side Effects

• Allergic reactions: including anaphylaxis, rash, or bronchospasm.
• Nephrogenic systemic fibrosis (NSF): rare fibrotic disorder in patients with severe renal impairment.
• Severe hypotension: sudden drop in blood pressure requiring medical attention.
• Seizures: infrequent neurologic events.
• Cardiac arrest: extremely rare but life‑threatening event.

Use of gadodiamide requires careful assessment of patient risk factors.

• Renal function assessment: evaluate kidney function before administration, especially in patients with impaired renal function.
• Pregnancy: use only if clearly needed; category C indicates potential risk.
• Breastfeeding: consider potential exposure and discuss with a healthcare professional.
• History of allergic reactions: assess prior contrast media reactions before use.
• Concurrent nephrotoxic drugs: monitor renal status closely when combined with other nephrotoxic agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gadodiamide may interact with other agents that affect renal function or contrast safety.

Major Interactions (Avoid)

• Severe renal impairment: increased risk of nephrogenic systemic fibrosis; avoid or select alternative contrast.
• High‑dose iodinated contrast agents: combined use may heighten nephrotoxicity.
• Concurrent gadolinium‑based agents: avoid simultaneous administration of multiple gadolinium products.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may alter renal clearance, requiring monitoring of kidney function.
• ACE inhibitors or ARBs: can affect renal perfusion; observe renal parameters during co‑administration.